Skip to main content

    ADMET-AI

    Predict 41 TDC ADMET endpoints and 8 RDKit descriptors from SMILES with Chemprop-RDKit graph neural networks — hERG, AMES, DILI, CYP450 and clearance.

    admet-ai

    ADMET-AI predicts absorption, distribution, metabolism, excretion, and toxicity liabilities across a broad panel of endpoints straight from SMILES. Reach for it for a fast, broad first screen — early hit triage and library-scale prioritization — when you want to flag safety and pharmacokinetic risks before committing synthesis. ADMETLab3, which offered a wider endpoint set, is no longer available, so ADMET-AI is the platform's ADMET predictor. See what you can achieve for the full set.

    How ADMET-AI results compare to the bench

    What an ADMET-AI probability has been shown to agree with, why the comparison is one step removed from an assay, and which endpoints do not translate.

    Try it

    ADMET-AI integration in .bloom* platform

    ADMET-AI is a state-of-the-art machine learning platform for fast and accurate ADMET property prediction. Developed by researchers at Stanford University, it uses Chemprop-RDKit graph neural networks trained on 41 ADMET datasets from the Therapeutics Data Commons (TDC). Through .bloom*'s webapp, you can screen compound libraries for pharmacokinetic and safety properties without complex setup.

    Citations

    Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, Shivnaraine RV, Zou J. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics. 2024 Jul 1;40(7):btae416. doi: 10.1093/bioinformatics/btae416

    Huang K, Fu T, Gao W, Zhao Y, Roohani Y, Leskovec J, Coley CW, Xiao C, Sun J, Zitnik M. Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development. NeurIPS Datasets and Benchmarks. 2021. arXiv: 2102.09548 · https://tdcommons.ai

    Technical foundation

    Model architecture

    ADMET-AI uses Chemprop-RDKit, a graph neural network architecture that combines:

    • Message passing neural networks for molecular graph representation
    • RDKit-computed molecular descriptors as additional features
    • Trained on the Therapeutics Data Commons (TDC) ADMET Benchmark datasets

    Performance benchmarks

    Every figure below is author-reported, carries the dataset and sample size it was measured on, and comes from TDC's scaffold-split test sets — the setting where the model must generalise to chemical series it did not train on. Read how ADMET-AI results compare to the bench before acting on any of them.

    • Toxicity classifiers: hERG AUROC 0.840 (hERG, n = 655) · mutagenicity 0.850 (AMES, n = 7278) · drug-induced liver injury 0.887 (DILI, n = 475).
    • Strongest regression endpoints: aqueous solubility MAE 0.761 log mol/L (AqSolDB, n = 9982) and lipophilicity MAE 0.467 log-ratio (AstraZeneca, n = 4200) — best on the leaderboard for both.
    • Weakest endpoints, and they are the pharmacokinetic ones: half-life Spearman 0.239 (Obach, n = 667) and volume of distribution Spearman 0.389 (Lombardo, n = 1130). Do not read these as quantities.
    • Highest average rank across the 22 TDC ADMET Benchmark Group datasets as of the paper's snapshot (4 October 2023). That is an average: on the same snapshot the model ranked 10th on volume of distribution and 11th on blood–brain barrier.
    • Fastest of the public ADMET web servers measured in the 2024 paper — a 45% time reduction over the next fastest for 1000 molecules. That comparison is on speed only, not accuracy.

    Webapp input and processing capabilities

    Compound input methods

    Direct SMILES entry:

    • Paste individual SMILES strings with instant validation
    • Real-time structure preview and property calculation
    • Support for stereochemistry and complex molecules

    Batch file processing:

    • Upload CSV files with SMILES in the first column
    • Support for multi-molecule SDF files
    • Automatic format detection and parsing
    • Progress tracking for large datasets (thousands of compounds)

    Integration with other tools:

    • Direct import from generative chemistry tools (DeepPurpose, AiZynthFinder)
    • Connection to virtual screening results
    • Import from compound library searches (ZINC, PubChem)

    Prediction endpoints available

    ADMET-AI computes 8 physicochemical properties using RDKit and predicts 41 ADMET properties across the following categories:

    Absorption predictions:

    • Caco-2 permeability: Intestinal absorption prediction
    • HIA: Human intestinal absorption classification
    • Pgp inhibition/substrate: P-glycoprotein interaction predictions
    • Bioavailability: Oral bioavailability classification

    Distribution predictions:

    • BBB permeability: Blood-brain barrier penetration
    • PPB: Plasma protein binding (fraction unbound)
    • VDss: Volume of distribution at steady state

    Metabolism predictions:

    • CYP450 inhibition: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 inhibition
    • CYP450 substrate: Substrate classification for CYP2C9, CYP2D6, CYP3A4

    Excretion predictions:

    • Clearance: hepatocyte and microsomal clearance, as regression values in the assay's own units. There is no renal clearance model
    • Half-life: a regression value in hours, not a stability class — and the weakest endpoint the model reports

    Toxicity predictions:

    • hERG inhibition: cardiotoxicity risk (QT prolongation)
    • AMES toxicity: mutagenicity prediction
    • DILI: drug-induced liver injury risk
    • Skin reaction: dermal toxicity potential (n = 404)
    • Carcinogenicity: carcinogen classification (n = 278)
    • Clinical trial toxicity and acute toxicity (LD50): two separate endpoints — a binary ClinTox probability and an LD50 regression value
    • Tox21 panel: 12 nuclear-receptor and stress-response assay endpoints. These are a toxicity screen, not an off-target selectivity panel

    Quality control and validation

    Structure processing:

    • Automatic SMILES canonicalization and standardization
    • Salt stripping and neutralization
    • Duplicate detection and removal
    • Structure validation with detailed error reporting

    Prediction reliability:

    • Confidence scores for each prediction
    • Applicability domain assessment based on training set similarity
    • Model version tracking for reproducibility
    • Uncertainty quantification via 5-model ensemble predictions

    No reliability field tells you whether the model has seen chemistry resembling your molecule. That is the dominant caveat on every number here, and it is unmeasured — see translatability.

    When to use ADMET-AI in drug discovery

    Early compound evaluation

    Virtual screening triage:

    • Filter large compound libraries before synthesis
    • Prioritize compounds with favorable ADMET profiles
    • Flag molecules with potential safety concerns
    • Order the wet-lab queue — not replace it. No endpoint here is validated to substitute for its assay

    Lead optimization:

    • Assess ADMET properties of hit compounds
    • Guide medicinal chemistry optimization decisions
    • Balance potency with developability parameters
    • Identify compounds requiring formulation development

    Compound library design:

    • Evaluate virtual compound collections
    • Design libraries with improved ADMET properties
    • Assess synthetic accessibility alongside drug-like properties
    • Optimize for multiple parameter objectives

    Safety triage

    These are internal triage uses. ADMET-AI is not qualified under ICH M7 or any other guideline that admits a computed prediction in place of a test, so nothing here is suitable for a regulatory submission.

    Safety profiling:

    • Early flagging of toxicological liabilities
    • A cardiotoxicity signal (hERG probability) to prioritize a patch-clamp assay
    • A first look at metabolic liabilities

    Drug metabolism:

    • CYP inhibition and substrate probabilities — these are inputs to a drug–drug interaction assessment, not a DDI assessment
    • Hepatocyte and microsomal clearance estimates, for ranking rather than as values
    • Planning which in vitro metabolism studies to run first

    It does not predict metabolic pathways, metabolite structures, or drug–drug interactions.

    Performance characteristics

    Batch processing efficiency

    Scalability:

    • Support for thousands of compounds per job
    • Parallel processing with automatic load balancing
    • GPU acceleration for large prediction batches
    • Memory optimization for high-throughput screening

    Error handling:

    • Individual compound failure handling
    • Detailed error reporting per molecule
    • Batch continuation despite individual failures
    • Retry logic for transient service issues

    Result management

    Output formats:

    • CSV exports: Tabular format for spreadsheet analysis
    • JSON artifacts: Structured data for programmatic access
    • Interactive dashboards: Real-time result visualization
    • Statistical summaries: Distribution analysis across datasets

    Result interpretation:

    • Scoring systems: Standardized risk categories (Low/Medium/High)
    • Confidence intervals: Prediction uncertainty quantification
    • Comparative analysis: Side-by-side evaluation of compound series
    • Trend identification: Property optimization patterns

    Integration with .bloom* ecosystem

    Upstream data sources

    Chemistry tools:

    • DeepPurpose: Evaluate generated molecule properties
    • AiZynthFinder: Assess synthetic intermediates
    • Fragment libraries: Screen building block collections
    • Virtual screening: ADMET evaluation of docking hits

    Downstream applications

    Decision support:

    • Multi-parameter optimization workflows
    • Compound advancement criteria definition
    • Risk-benefit analysis frameworks
    • Portfolio prioritization strategies

    Experimental planning:

    • Guide in vitro assay selection
    • Plan in vivo pharmacokinetic studies
    • Design formulation development strategies
    • Optimize preclinical candidate selection

    Workflow automation

    High-throughput pipelines:

    • Automated batch processing workflows
    • Integration with compound management systems
    • Real-time result monitoring and alerting
    • Quality control and data validation

    Research collaboration:

    • Shared prediction results across teams
    • Integration with electronic lab notebooks
    • Audit trails for regulatory compliance
    • Reproducible analysis workflows

    Chat Usage

    Example Prompts

    • "Run ADMET-AI on CC(=O)Oc1ccccc1C(=O)O" (aspirin)
    • "Screen these 10 compounds through ADMET-AI and export results as CSV"
    • "Predict drug-likeness for gefitinib and erlotinib — compare hERG profiles"

    Workflow Chaining

    • Feeds into: Compound Passport (ADMET section), comparison tables
    • Accepts from: PubChem, ZINC, ChEMBL (compound SMILES), REINVENT/GenMol (generated molecules)

    FAQ

    Was this page helpful?

    Loading...